P-Cure Overview
P-Cure has developed a proprietary, imaging-based solution for cost-effective cancer treatment using proton radiation. The companys delivery system enables the use of inexpensive fixed-beam technologies for the treatment of all cancer indications. The P-Cure system aims to improve treatment accuracy, expand the number of new indications, and shorten the length of treatment procedures. The system is compatible with existing accelerators, beam lines, and treatment protocols. The P-ARTIS is a comprehensive and fully integrated solution to treat patients with protons. It includes diagnostic-quality volumetric imaging, a robotic positioning system, patient support systems, real-time X-ray imaging, operating panels, and workstations. The P-ARTIS 4D volumetric imaging system is equipped with the Brilliance Big Bore CT integrated into the sliding system. The setup enables patients to be scanned in the treatment position while being kept stationary.
Cumulative Funding Raised Over Time ($)
$10.0MDec 2016
$21.0MFeb 2021
$36.0MJul 2019
Latest News
growth-positive
New form of proton therapy for cancer starts trial in Jerusalem
P-Cure, an Israeli company, has developed a new form of proton therapy for cancer treatment. The therapy, which uses high-energy beams of protons, is known for its precise targeting of tumors. However, the large size and high cost of proton therapy machines have limited its adoption. P-Cures solution, developed in collaboration with Hadassah Medical Center, involves a moving chair that allows for pinpointed treatment from 360 degrees. The smaller size of P-Cures system makes it more accessible for hospitals. Hadassah Medical Center has started a clinical trial for the Israeli-made proton therapy. The trial aims to improve patients chances of effective treatment and reduce toxicity. The trial is expected to address the obstacle of limited space for proton therapy installations in hospitals.
CustomersPartners
growth-positive
P-Cure Prepares to Meet Market Demand by Setting Up the Largest Production Facility of Proton Therapy Systems in the World
P-Cure Ltd. has announced the establishment of a new production facility in Weifang, China, to manufacture its 360o Gantry-less Adaptive Proton Therapy System. The facility, spanning over 400,000 square feet, will operate alongside the existing production facility in Israel to meet global market demand. The new facility will allow P-Cure to shrink the cost and lead-time of product delivery, as well as provide spare parts and customer support. P-Cure is the only provider of proton therapy that can install the latest cancer-fighting technology within existing radiotherapy vaults. The company aims to meet the growing demand for its compact and precise proton therapy solution. P-Cure is also expecting FDA and CE approvals for additional product configurations.
Expand
growth-positive
P-Cure Demonstrates the Proton Therapy Equipment Can Now Be Installed In Existing Radiation Therapy Rooms
P-Cure, an Israeli company, has developed a system for installations in existing radiation therapy rooms. The system targets the largest radiotherapy market and aims to replace equipment. The article discusses the development of this system.
Customers
growth-positive
P-Cure raises $11M to fight cancer with protons
Israeli company P-Cure has closed an $11 million funding round led by Popular Line Medical Group. P-Cure develops proton-based cancer therapy, which promises a cheaper and more effective treatment for cancerous tumors. Their P-Artis system utilizes proton radiation to disrupt cancer cells and destroy them. The funding will be used to advance clinical collaboration, enhance U.S. sales efforts, and create additional clinical data to support marketing goals. P-Cure plans to make their solution accessible to all oncology centers that offer radiotherapy.
Investment
growth-positive
P-Cure Secures CE Marking for Breakthrough Image Guided Positioning System
P-Cure Ltd, a developer and supplier of a comprehensive 360°-gantry-less adaptive proton therapy solution, has received CE marking approval for its P-ARTIS System. This approval allows the company to market and sell the product in Europe. The P-ARTIS System is a vital development for enhanced patient treatment and is part of the newly developed full P-Cure proton therapy system, which is currently being submitted for FDA clearance. The system enables accurate image guided positioning of patients in the seated position for radiation therapy, including proton therapy. It reduces capital and operating costs and expands the availability of proton therapy to more patients. The P-Cure System aims to substantially reduce the cost and size of proton therapy centers and reduce the time from planning to treatment.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $36M |
| Last funding | $11M |
| Stage | B |
| Rounds | 4 |
| Investors | 4 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.p-cure.com |
Locations
Shilat, Israel
China
Akron, OH, USA
Photos & Videos
2 item(s)
P-Cure Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersMedical Devices IndustryMedical EquipmentCore Technology
Machinery & RoboticsPlatforms & InterfacesSoftwareTags (14)
imagingcancerct-scanx-rayoncologymedical-technologieshospitalsmedical-equipmentclinicsdoctorshealthcare-providersdiagnosticstreatmentsoptronicsGeographic Markets
EuropeUnited StatesIndiaP-Cure Financials
$36M
Total funding
Undisclosed
Capital raised
$11M
Last funding
B
Funding stage
4
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$10.0MDec 2016
$21.0MFeb 2021
$36.0MJul 2019
Private Equity Funding
Undisclosed Round
Feb 2021
$11M
Popular Line Medical
B Round
Jul 2019
$15M
StarVest Partners, Popular Line Medical, Lions Peak Capital, Everett Partners
A Round
Dec 2016
$10M
Lions Peak Capital, Everett Partners
Non-Equity Funding
GrantEvent
Undisclosed
Office of the Chief Scientist
P-Cure Lifecycle
Cumulative Funding Raised Over Time
$10.0MDec 2016
$21.0MFeb 2021
$36.0MJul 2019
All Events
Undisclosed Round
Feb 2021
$11M
Popular Line Medical
B Round
Jul 2019
$15M
StarVest Partners, Popular Line Medical, Lions Peak Capital, Everett Partners
A Round
Dec 2016
$10M
Lions Peak Capital, Everett Partners
GrantEvent
Undisclosed
Office of the Chief Scientist
P-Cure News
14 articles
growth-positive
New form of proton therapy for cancer starts trial in Jerusalem
P-Cure, an Israeli company, has developed a new form of proton therapy for cancer treatment. The therapy, which uses high-energy beams of protons, is known for its precise targeting of tumors. However, the large size and high cost of proton therapy machines have limited its adoption. P-Cures solution, developed in collaboration with Hadassah Medical Center, involves a moving chair that allows for pinpointed treatment from 360 degrees. The smaller size of P-Cures system makes it more accessible for hospitals. Hadassah Medical Center has started a clinical trial for the Israeli-made proton therapy. The trial aims to improve patients chances of effective treatment and reduce toxicity. The trial is expected to address the obstacle of limited space for proton therapy installations in hospitals.
CustomersPartners
growth-positive
P-Cure Prepares to Meet Market Demand by Setting Up the Largest Production Facility of Proton Therapy Systems in the World
P-Cure Ltd. has announced the establishment of a new production facility in Weifang, China, to manufacture its 360o Gantry-less Adaptive Proton Therapy System. The facility, spanning over 400,000 square feet, will operate alongside the existing production facility in Israel to meet global market demand. The new facility will allow P-Cure to shrink the cost and lead-time of product delivery, as well as provide spare parts and customer support. P-Cure is the only provider of proton therapy that can install the latest cancer-fighting technology within existing radiotherapy vaults. The company aims to meet the growing demand for its compact and precise proton therapy solution. P-Cure is also expecting FDA and CE approvals for additional product configurations.
Expand
growth-positive
P-Cure Demonstrates the Proton Therapy Equipment Can Now Be Installed In Existing Radiation Therapy Rooms
P-Cure, an Israeli company, has developed a system for installations in existing radiation therapy rooms. The system targets the largest radiotherapy market and aims to replace equipment. The article discusses the development of this system.
Customers
growth-positive
P-Cure raises $11M to fight cancer with protons
Israeli company P-Cure has closed an $11 million funding round led by Popular Line Medical Group. P-Cure develops proton-based cancer therapy, which promises a cheaper and more effective treatment for cancerous tumors. Their P-Artis system utilizes proton radiation to disrupt cancer cells and destroy them. The funding will be used to advance clinical collaboration, enhance U.S. sales efforts, and create additional clinical data to support marketing goals. P-Cure plans to make their solution accessible to all oncology centers that offer radiotherapy.
Investment
growth-positive
P-Cure Secures CE Marking for Breakthrough Image Guided Positioning System
P-Cure Ltd, a developer and supplier of a comprehensive 360°-gantry-less adaptive proton therapy solution, has received CE marking approval for its P-ARTIS System. This approval allows the company to market and sell the product in Europe. The P-ARTIS System is a vital development for enhanced patient treatment and is part of the newly developed full P-Cure proton therapy system, which is currently being submitted for FDA clearance. The system enables accurate image guided positioning of patients in the seated position for radiation therapy, including proton therapy. It reduces capital and operating costs and expands the availability of proton therapy to more patients. The P-Cure System aims to substantially reduce the cost and size of proton therapy centers and reduce the time from planning to treatment.
CustomersPartners
growth-positive
Cancer Therapy Startup P-Cure Raises $15 Million
Cancer therapy startup P-Cure Ltd. has completed a $15 million series B funding round led by Popular Line Medical Group Limited. The funding will be used to expand the companys development team, production capacity, and marketing efforts in Israel. P-Cure develops proton radiation technology for the treatment of cancer, which aims to provide more efficient and focused treatment compared to conventional radiation. The company has raised a total of $30 million to date and currently has 23 employees. P-Cures technology will soon be deployed in medical centers in the U.K. and China.
InvestmentExpand
growth-positive
P-Cure says it can beam tumors away at half the cost
Israeli startup P-Cure has developed a technology to reduce the costs of proton therapy by eliminating the need for an expensive gantry. This technology allows for greater access to the treatment and increases its benefits. Proton therapy is expected to replace X-ray treatment and is covered by Medicare and state insurers in the US. P-Cure has raised $10 million from private investors and has installed a system at Northwestern Medicine Chicago Proton Center. The company has also reached collaboration agreements with Philips Healthcare and hospitals in Korea and Israel. P-Cure is raising funds to expand its customer base globally and in Israel and to scale up its manufacturing facility.
CustomersInvestment
growth-positive
P-Cure revolutionazie Proton Radiation treatment - Israel Electronics News
Israeli med-tech company P-Cure has developed a new approach to radiation treatment facilities, reducing the cost of proton treatment by half. The company has raised $10 million and is in the midst of a series B funding round. P-Cure is preparing to outsource the production of its proton treatment systems to an external contractor, which will increase its production capacities. The company has supplied its first operational system to the NorthWestern hospital in Chicago, United States, and is now producing two further systems for a major hospital in London, England.
InvestmentCustomersPartners
growth-positive
P-Cure installs hospital proton therapy system
P-Cure, an Israeli company specializing in proton radiation for cancer treatment, has installed its first system at Northwestern University Feinberg School of Medicine in Chicago. The companys system is cheaper and more accurate than traditional proton radiation systems. P-Cure has received marketing approval for its products and this installation marks its first official system. The universitys investment in the system demonstrates confidence in the product. Clinical trials for marketing and insurance reimbursement will begin after installation. P-Cures technology allows for more effective and comfortable treatment, accommodating patients in a sitting position. The company has raised $10 million to date and plans to start another financing round in early 2017.
InvestmentPartnersExpand
growth-positive
Northwestern Medicine Chicago Proton Center To Offer P-Cure Upright Diagnostic Quality Imaging Technology
P-Cure, Ltd has received FDA approval to market its P-ARTIS CT scanner system, which allows for CT scanning of patients in a seated position. The Northwestern Medicine Chicago Proton Center will be the first to use this innovative imaging technology for lung cancer patients. The upright CT scanning system is expected to provide more precise targeting of tumors during proton therapy treatment. The seated position for imaging and treatment is also expected to increase patient comfort and decrease tumor motion. P-Cure aims to create more clinical flexibility for proton centers and establish cost-effective proton therapy services.
Customers
growth-positive
Making proton therapy available to more cancer patients
Israeli company P-Cure has received FDA approval for its compact and cost-effective proton therapy system. The system uses diagnostic-quality computed tomography (CT) to enable proton-therapy treatment planning, positioning, and delivery for cancer patients in a seated position. The company has already sold three systems and expects further sales. P-Cure aims to make proton therapy more accessible and affordable, as currently only 50 out of 8,000 radiation oncology centers worldwide use protons. The company is raising money to expand its operations.
Customers
growth-positive
FDA Clears P-Cure Upright Imaging Solution for Proton Therapy Enhancement
P-Cure, a leading provider of Patient-Centric solutions for proton therapy, has received FDA approval for its patented upright imaging solution. The approval allows P-Cure to offer greater patient comfort, less internal organ movement, and better accuracy in proton beam delivery. The company aims to make proton therapy more widely available and attainable by reducing capital and operating costs. The FDA clearance for P-Cures upright imaging technology is expected to enable all oncology centers and hospitals globally to establish cost-effective proton therapy services. P-Cures first product was cleared by the FDA in 2010.
CustomersInvestment
growth-positive
Philips Healthcare teams with P-Cure on proton therapy
Philips has partnered with P-Cure, an Israel-based medical device company, to advance P-Cures proton therapy technology. The partnership allows P-Cure access to Philips CT imaging technology to improve cancer treatment. The collaboration aims to provide the next generation of proton therapy systems, reducing cost and improving treatment quality and accessibility. The partnership is expected to have a positive impact on Philips growth.
Partners
growth-positive
http://www.marketwired.com/press-release/p-cure-opens-us-office-and-appoints-coo-1513258.htm
Cipher Mining announces June 2023 operational update.
Investment
P-Cure Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 45 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
P-Cure Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Natalia Golczar |
| Registrar ID | 513900860 |
| Crunchbase | p-cure |
| Phone | +97286373030 |
| Creator | Rachel Wain |
| Creator email | rachelwain18@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wain@gmail.com |
| Last update | 2022-08-09T00:00:00.000Z |
| Created | 2015-01-07T00:00:00.000Z |